A research study led by Teresa Quattrin, MD, could prove beneficial for children and young adults with newly-diagnosed Type 1 diabetes.
Published December 16, 2020
A Phase 2 research study led by Teresa Quattrin, MD, UB Distinguished Professor of pediatrics and senior associate dean for research integration, shows that the drug golimumab preserves beta-cell function in children and young adults with newly-diagnosed Type 1 diabetes for at least a year after diagnosis.
Research Published in New England Journal of Medicine
The study published on Nov. 19 in The New England Journal of Medicine represents a major step forward in the effort to find ways to preserve the insulin-making capabilities of children and young adults newly diagnosed with Type 1 diabetes.
The study demonstrates that golimumab, an anti-tumor-necrosis-factor (TNF) therapy, reduced the amount of injected insulin required by children and young adults with newly-diagnosed Type 1 diabetes by preserving their ability to produce insulin on their own, called endogenous insulin.
The need for less injected insulin is a major quality of life improvement for patients with Type 1 diabetes, according to the researchers.
Golimumab, marketed as Simponi, is currently used in the treatment of rheumatoid arthritis, ulcerative colitis and other autoimmune conditions. However, it is not approved by the U.S. Food and Drug Administration for the treatment of Type 1 diabetes.
Quattrin, first author on the study, also presented the findings on June 13 at the annual meeting of the American Diabetes Association (ADA).
The most important finding of our work is that this drug, golimumab, is a potential disease-modifying agent for newly diagnosed Type 1 diabetes, says Quattrin, attending pediatric endocrinologist at the Diabetes Center atUBMD PediatricsandOishei Childrens Hospital. The main goal of the study was to see if golimumab could preserve beta-cell function in these newly-diagnosed patients and it does.
This was assessed by measuring the amount of C-peptide in patients blood during a four-hour mixed meal tolerance test. Because C-peptide reflects only insulin made by the body and not injected insulin, C-peptide levels reveal how well the pancreas is producing insulin.
Higher C-Peptide Levels After 1 Year
Patients treated with golimumab had a higher C-peptide level at week 52 compared to placebo.
This was statistically significant; thus the study met its primary goal, Quattrin says.
Quattrin adds that 41.1 percent of participants receiving golimumab had an increase or a less than 5 percent decrease in C-peptide compared to only 10.7 percent in the placebo group.
Nearly 43 percent of those who received golimumab were in partial diabetes remission (also known as the honeymoon phase) versus 7.1 percent of those receiving placebo. The definition of partial remission was based on insulin dose and blood sugar control levels as indicated by hemoglobin A1C, a measurement of average blood sugar levels over three months.
Blood Sugar Control With Less Insulin
Quattrin explains that a child with Type 1 diabetes requires about 1 unit of insulin per kilogram of body weight per day. That means that a child weighing about 65 pounds typically requires about 30 units of injected insulin per day once they are out of the partial remission period about 3 to 6 months after diagnosis.
In this study, both golimumab and placebo groups achieved good blood sugar control, but patients treated with golimumab achieved it with less insulin, Quattrin says.
During the 52 weeks, insulin dose increased only slightly for those on golimumab 0.07 units per kilogram per day versus 0.24 units per kilogram per day for those on placebo study.
In a post-hoc analysis an analysis conducted after the conclusion of the clinical trial those younger than 18 years had 36 percent fewer episodes where blood sugar was less than 54 mg per deciliter, designated by the ADA as level 2 hypoglycemia.
This is important clinically because low blood sugar reactions are dangerous and can even be fatal if untreated. Low blood sugar levels also require immediate attention, often causing the child to be removed from classroom or recreation activities, compromising quality of life.
UMBD Pediatrics, Oishei Among Trial Sites
The drug is self-administered as a subcutaneous injection every two weeks. No serious side effects related to the study drug such as serious infections were reported.
The randomized, controlled clinical trial was conducted at 27 centers throughout the U.S., including at theDiabetes Center at UBMD Pediatrics andOishei Childrens Hospital in Buffalo. It involved 84 patients, ages 6 to 21 years, with two-thirds receiving golimumab and one-third receiving placebo starting within 100 days from diagnosis.
Throughout three decades as a leading researcher in pediatric endocrinology, Quattrin has been interested in finding ways to extend the remission, or honeymoon period, to preserve the ability of recently diagnosed Type 1 diabetes patients to continue to make insulin on their own.
The current study took place on the basis of positive findings in animal models, as well as Quattrins work with patients treated at the Diabetes Center at UBMD Pediatrics and Oishei Childrens Hospital. It confirms results published by her team in 2009 where in a randomized pilot study 10 patients received another TNF inhibitor and eight received placebo starting within 28 days from diagnosis.
The results of this small proof-of-concept study strongly suggested that this class of drugs might be able to preserve beta-cell function in newly diagnosed patients with Type 1 diabetes.
Jacobs School Faculty Are Sub-Investigators
Jacobs School of Medicine and Biomedical SciencesDepartment of Pediatrics sub-investigators in the research are:
They were supported by the pediatric diabetes-endocrinology research team at the Diabetes Center at UBMD Pediatrics and Oishei Childrens Hospital, led by Amanda House.
Other co-authors of the research presented at the ADA and on the New England Journal of Medicine paper were from Emory University, the University of Colorado, the University of Florida and Janssen Research & Development LLC. The World Without Disease Accelerator a group within Janssen funded the study.
Read more from the original source:
Kids With Type-1 Diabetes Helped by Anti-TNF Therapy - ubmd.com
- Global report on diabetes - World Health Organization (WHO) - October 22nd, 2024
- Ultra-processed food may be particularly harmful for people with diabetes, scientists warn - The Independent - October 22nd, 2024
- New drugs may be able to treat multiple problems beyond diabetes - The Straits Times - October 22nd, 2024
- Best Fruits for Diabetes (and What To Avoid) - Health Essentials - October 22nd, 2024
- Cutting Sugar May Reduce Your Diabetes, Stroke, and Depression Risk - Healthline - October 22nd, 2024
- Can Diabetes Care Teams Improve Patient Outcomes and Value? - Medscape - October 22nd, 2024
- Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD - MD Magazine - October 22nd, 2024
- High expression of CNOT6L contributes to the negative development of type 2 diabetes - Nature.com - October 22nd, 2024
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic... - October 22nd, 2024
- Dental teams could detect undiagnosed diabetes in more than one million people with new care pathway - Nature.com - October 22nd, 2024
- Groundbreaking Innovations in Diabetes Care: Highlights from the 2024 Diabetes Technology Meeting - Beyond Type 1 - October 22nd, 2024
- COVID-19 linked to type 2 diabetes onset in children - Medical Xpress - October 22nd, 2024
- The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel... - October 22nd, 2024
- Does microdosing Ozempic work? What experts are saying about the diabetes drug also used for weight loss - Medical Xpress - October 22nd, 2024
- The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024 - Managed Healthcare Executive - October 22nd, 2024
- The overexpression of human amylin in pancreatic cells facilitate the appearance of amylin aggregates in the kidney contributing to diabetic... - October 22nd, 2024
- RNAO releases updated guidelines for diabetic foot ulcer care - Benefits and Pensions Monitor - October 22nd, 2024
- COVID-19 raises the risk of type 2 diabetes in children, study reveals - News-Medical.Net - October 22nd, 2024
- Semaglutide: What impact does it really have on heart health? - Medical News Today - October 22nd, 2024
- Glucose monitors for diabetes have finally been funded but a chronic workforce shortage will limit the benefits - The Conversation - October 22nd, 2024
- Early vs Late Fast Window: Is One More Effective? - Medscape - September 13th, 2024
- Breakthrough T1D Walk to Cure Type 1 Diabetes - KATU - September 13th, 2024
- Foods That May Increase Kids' Risk of Type 1 Diabetes Revealed - Newsweek - September 13th, 2024
- Beds and Herts patients to be re-tested in diabetes results error - BBC.com - September 13th, 2024
- This common habit increases your diabetes risk by 50%; Heres how to fix it - The Economic Times - September 13th, 2024
- Elevated risk of pre-diabetes and diabetes in people with past history of COVID-19 in northeastern Nigeria - BMC Public Health - September 13th, 2024
- Study links bananas, oats and yoghurt to greater diabetes risk in susceptible children - The Guardian - September 13th, 2024
- Could the Norton research teams studying diabetes and Alzheimer's come up with a cure? - Courier Journal - September 13th, 2024
- Weight loss, better beta-cell function tied to long-term glycemic control with tirzepatide - Healio - September 13th, 2024
- Study finds weekly insulin injections as effective for diabetes as daily shots - UPI News - September 13th, 2024
- Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Heres what the science says - The Conversation - September 13th, 2024
- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes - PR Newswire - September 13th, 2024
- Dining with Diabetes workshops offered - The Courier-Express - September 13th, 2024
- Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing - News-Medical.Net - September 13th, 2024
- The menopause can increase your likelihood of developing heart disease, type 2 diabetes and hypertension but exercise can help lower risk - The... - September 13th, 2024
- Artificial pancreas shows promise in people with type 1 diabetes on kidney dialysis - MSN - September 13th, 2024
- How an Indian executive battled flesh-eating disease and diabetes, and won - South China Morning Post - September 13th, 2024
- India brings early Diabetic Retinopathy detection to the last mile with Artificial Intelligence - PR Newswire - September 13th, 2024
- Why this diabetes drug may be the answer to NASA search for radiation protection - Texas Public Radio - September 13th, 2024
- The National Association of Chain Drug Stores and the American Diabetes Association Promote Nutrition Security and its Role in Preventing and Managing... - September 13th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023
- Diabetes and Hearing Loss with Concept by Iowa Hearing | Paid Content - Local 5 - weareiowa.com - May 9th, 2023
- COUNTY COLUMN: Learn to Live well with diabetes at The Well - Norman Transcript - May 1st, 2023
- Want to Cut Type 2 Diabetes Risk? This High-fat Food Can Be the Answer, According to New Study - Revyuh - May 1st, 2023
- Diabetes: What It Is, Causes, Symptoms, Treatment & Types - March 13th, 2023
- A number of healthtech startups claim they can reverse Type 2 diabetes. But caveats apply, caution doctors - Economic Times - March 13th, 2023
- Tampa doctor who lost brother to diabetes calls insulin price cut a 'game changer' - ABC Action News Tampa Bay - March 5th, 2023
- New study suggest people previously infected with COVID-19 could have increased risk for diabetes - CBS Los Angeles - February 16th, 2023
- Diabetes Symptoms, Causes, & Treatment | ADA - October 15th, 2022
- A nutritionist with type 1 diabetes shares the top 5 'food swaps' she eats to manage her blood sugar - CNBC - October 15th, 2022
- Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today - October 15th, 2022
- Milton teen involved in launch of diabetes support program - Milton Daily Standard - October 15th, 2022
- Providers Now Have Free Access to Latest Diabetes Technology in One Place - PR Newswire - October 15th, 2022
- 5 Modifiable Factors in Women with History of Gestational Diabetes Mellitus That Can Reduce the Risk of T2D - Pharmacy Times - October 15th, 2022
- BCMH the stoy of Diabetes and Determination - 921News - October 15th, 2022
- Can skipping a meal lead to diabetes and fat around abdomen? - The Indian Express - October 15th, 2022
- Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 -... - October 15th, 2022
- Diabetes: Symptoms, risks, and prevention - Wilmington News Journal, OH - July 17th, 2022
- Diabetes symptoms: The sign of nerve damage that often strikes at night - severe - Express - July 17th, 2022
- Local Teen Brings Smiles and Health Kits to Kids with Diabetes - River Journal Staff - July 17th, 2022
- Type 3 diabetes: symptoms, causes and treatments - Livescience.com - July 17th, 2022
- Diabetes Travel Essentials and Tips for the Approximately 21 Million Americans that Must Manage Their Diabetes While on Vacation - PR Newswire - July 17th, 2022
- A type of 'step therapy' is an effective strategy for diabetic eye disease - National Institutes of Health (.gov) - July 17th, 2022
- Diabetes education: one in five search results for diabetes lack reliable information - Open Access Government - July 17th, 2022
- Arch City Kids Theater Troupe Fights Type 1 Diabetes With Its Annual Revue - Broadway World - July 17th, 2022
- Nutrigenomics Testing Industry Forecast to 2027 - Insights Into Obesity, Diabetes, Cancer, and Cardiovascular Disease Applications -... - July 17th, 2022
- Harvard Scientists Have Developed a Revolutionary New Treatment for Diabetes - SciTechDaily - June 16th, 2022
- Do Viruses and Coxsackievirus Cause Type 1 Diabetes? - Healthline - June 16th, 2022
- Diabetes Week: Types 1 and 2 symptoms, causes and prevention - Yahoo Entertainment - June 16th, 2022
- Diabetes And Sex: Have Safe Sex While Managing Diabetes - MadameNoire - June 16th, 2022
- Diabetes Devices Market to Expand at the CAGR of 6.4% from 2019 to 2027, Increase in Prevalence of Diabetes Expected to Drive Global Market - BioSpace - June 16th, 2022
- Anemia and Diabetes: What You Should Know - Healthline - June 16th, 2022
- Patient Knowledge of Diabetes and CKD in an Inner-City Population - DocWire News - June 16th, 2022
- ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM - PR Newswire - June 16th, 2022
- Understanding the Link between Diabetes Care and Sickle Cell Disease | NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases... - June 16th, 2022
- Child type 2 diabetes referrals in England and Wales jump 50% amid obesity crisis - The Guardian - June 16th, 2022